Rising Incidence of Hepatocellular Carcinoma in the United States

El–Serag, Hashem B.; Mason, Andrew C.

doi:10.1056/nejm199903113401001

Cited by 2,684 publications

(1,701 citation statements)

References 19 publications

Supporting

Mentioning

1,635

Contrasting

Unclassified

Order By: Relevance

“…Moreover, important epidemiologic surveys have clearly demonstrated that HCC alone has significantly increased in the US over the past decade (El-Serag and Mason, 1999;El-Serag et al, 2003). What follows is a review of these reports.…”

Section: Incidence and Mortality Rates Of Hepatocellular Carcinoma Inmentioning

confidence: 99%

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

2006

View full text Add to dashboard Cite

Section: Incidence and Mortality Rates Of Hepatocellular Carcinoma Inmentioning

confidence: 99%

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

2006

View full text Add to dashboard Cite

“…Although HCC is common in southeast Asia and subSahara Africa, the incidence rate of HCC has continued to increase in the United States and western Europe over the past 25 years, and the incidence and mortality rates of HCC are expected to double over the next 10-20 years (El Serag and Mason, 1999;Davila et al, 2004;El Serag, 2004). Although much is known about both the cellular changes that lead to HCC and the etiological agents (i.e., HBV, HCV infection and alcohol) responsible for the majority of HCC, the molecular pathogenesis of HCC is not well understood (Thorgeirsson and Grisham, 2002;Llovet et al, 2003;Bruix et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Comparative and integrative functional genomics of HCC

2006

View full text Add to dashboard Cite

Global gene expression profiling of hepatocellular carcinoma (HCC) is a promising new technology that has already refined the diagnosis and prognostic predictions of HCC patients. This has been accomplished by identifying genes whose expression pattern is associated with clinicopathological features of HCC tumors. Molecular characterization of HCC from gene expression profiling studies will undoubtedly improve the prediction of treatment responses, selection of treatments for specific molecular subtypes of HCC and ultimately the clinical outcome of HCC patients. The research focus is now shifting toward the identification of genetic determinants that are components of the specific regulatory pathways altered in cancers, and that may constitute novel therapeutic targets. Here we review the recent advances in gene expression profiling of HCC and discuss the future strategies for analysing large and complicated data sets from microarray studies and how to integrate these with diverse genomic data.

show abstract

“…1 Unfortunately, the incidence and mortality associated with HCC is increasing steadily in the United States and Europe. 2,3 Current curative options, such as hepatic resection, liver transplantation and local ablative therapies, can be applied to a minority of patients in referral medical institutions. 4,5 Thus, in the majority of advanced HCC cases the prognosis is dismal because of underlying cirrhosis and poor tumor response to chemotherapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

The aim of this phase I clinical trial was to assess the feasibility and safety of intratumoral administration of a first-generation adenoviral vector encoding herpes simplex virus thymidine kinase (HSV-TK) gene (Ad.TK) followed by systemic ganciclovir to patients with advanced hepatocellular carcinoma (HCC). Secondarily, we have analyzed its antitumor effect. Ten patients were enrolled in five dose-level cohorts that received from 10 10 to 2 Â 10 12 viral particles (vp). Ad.TK was injected intratumorally and patients received up to three doses at 30-day intervals. Positron emission tomography was used to monitor TK gene expression. Ad.TK injection was feasible in 100% of cases. Treatment was well tolerated and dose-limiting toxicity was not achieved. Cumulative toxicity was not observed. Hepatic toxicity was absent even in cirrhotic patients. Fever, flu-like syndrome, pain at the injection site and pancytopenia were the most common side effects. No partial responses were observed and 60% of patients showed tumor stabilization of the injected lesion. Importantly, two patients who received the highest dose showed signs of intratumoral necrosis by imaging procedures. One of them achieved a sustained stabilization and survived for 26 months. In conclusion, Ad.TK can be safely administered by intratumoral injection to patients with HCC up to 2 Â 10 12 vp per patient.

show abstract

Rising Incidence of Hepatocellular Carcinoma in the United States

Abstract: An increase in the number of cases of hepatocellular carcinoma has occurred in the United States over the past two decades. The age-specific incidence of this cancer has progressively shifted toward younger people.

Cited by 2,684 publications

References 19 publications

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity

Comparative and integrative functional genomics of HCC

A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

Contact Info

Product

Resources

About